NFKB1 and non-small cell lung carcinoma: Furthermore, we found that inhibition of IGF1R or NF-κB p65 led to reversal of EMT phenotype with the concomitant partial restoration of sensitivity to gefitinib, suggesting that IGF1R/NF-κB pathway could be a novel target for treatment of advanced NSCLC patients.